Noradrenalin Kabi (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Noradrenalin Kabi, is a sympathomimetic presented as an injection for intravenous use. It is employed to raise blood pressure in patients experiencing severe hypotension, such as septic shock, cardiac arrest, or anaphylactic reactions.\n\nGNH India supplies Noradrenalin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Noradrenalin Kabi acts on the adrenergic system to restore vascular tone and cardiac output in critical care settings.\n\n- Hypotension: rapidly increases arterial pressure in patients with acute low blood pressure.\n- Septic shock: improves systemic vascular resistance to counteract distributive shock.\n- Cardiac arrest: supports coronary perfusion during resuscitation efforts.\n- Anaphylactic shock: counteracts severe vasodilation and maintains circulatory stability.

Adverse reactions may vary with dose, infusion rate, and patient condition.\n\nCommon Side Effects:\n- Tachycardia: increased heart rate due to beta‑1 stimulation.\n- Headache: result of rapid blood pressure changes.\n- Anxiety or restlessness: central nervous system activation.\n- Peripheral ischemia: reduced blood flow to extremities.\n- Nausea or vomiting: gastrointestinal upset.\n- Arrhythmias: ectopic beats or rhythm disturbances.\n\nSerious or Rare Side Effects:\n- Severe hypertension: excessive rise in blood pressure risking vascular injury.\n- Myocardial ischemia: reduced coronary perfusion leading to chest pain.\n- Tissue necrosis at infusion site: extravasation causing local damage.\n- Life‑threatening arrhythmias: ventricular tachycardia or fibrillation.\n- Pulmonary edema: fluid accumulation in lungs due to cardiac overload.\n- Profound bradycardia: paradoxical slowing of heart rate.

Use Noradrenalin Kabi only under continuous hemodynamic monitoring in an intensive care setting.\n\n- Cardiovascular disease: monitor for ischemia, arrhythmias, and excessive hypertension.\n- Peripheral vascular disease: avoid high infusion pressures to reduce risk of tissue necrosis.\n- Sepsis: titrate carefully to balance perfusion and vasoconstriction.\n- Concomitant vasopressors: adjust doses to prevent synergistic vasoconstriction.\n- Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine may interact with several drug classes, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors: risk of hypertensive crisis.\n- Other potent vasoconstrictors (e.g., phenylephrine): may cause severe hypertension.\n- Beta‑adrenergic antagonists: can blunt desired cardiac effects.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: additive hypotensive effects if norepinephrine is weaned.\n- Diuretics: may influence intravascular volume and response.\n- Calcium channel blockers: potential for altered vascular tone.\n- Anesthetic agents: may modify hemodynamic response during surgery.